Abstract The recombinant protein drug usually has a short half-life after intravenous (IV) or subcutaneous (SC) administration. The methods of prolonging the half-life of recombinant protein drug in common use are mainly based on three principles: 1, Amplifying the molecule weight of protein drug; 2, Making use of drug balance in the blood; 3, Reducing Immunogenicity. This review focuses on three methods: Analogy construction、PEGylation and Albumin fusion technology. The characteristics, half-life and immunogenicity problem of their products in the market and under development are summarized.
|
